// App-Quantinova.ai

DXT10 : Siponimod Affects Disability Progression in Patients with SPMS Independent of Relapse Activity: Results from the Phase 3 Expand Study

Researchers

Presenter

  • Bruce A C Cree

Principal Investigators

  • Robert J Fox

  • Gavin Giovannoni

  • Patrick Vermersch

  • Amit Bar-Or

  • Ralf Gold

  • Nicolas Rouyrre

  • Goeril Karlsson

  • Frank Dahlke

  • Ludwig Kappos

Medical Centers

  • Mellen Center for Multiple Sclerosis, Cleveland Clinic

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, UK

  • University of Lille, CHU Lille,

  • Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel

  • Weill Institute of Neurosciences, University of California, San Francisco

  • Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

  • St. Josef-Hospital/Ruhr-University Bochum

  • Novartis Pharma AG

Locations

  • United Kingdom

  • France

  • Switzerland

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Siponimod

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved